Predictive biomarkers for response to omalizumab in patients with severe allergic asthma: a meta-analysis.

Li, Yaqin; Li, Xiaoyan; Zhang, Biyu; Yu, Qing; Lu, Yanming

Li, Yaqin; Li, Xiaoyan; Zhang, Biyu; Yu, Qing; Lu, Yanming.

Afiliação

Li Y; Department of Pediatric, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li X; Department of Pediatric, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhang B; Department of Pediatric, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yu Q; Department of Pediatric, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lu Y; Department of Pediatric, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Expert Rev Respir Med ; 16(9): 1023-1033, 2022 09.

Article em En | MEDLINE | ID: mdl-35730466

Assuntos

Antiasmáticos; Asma; Adulto; Humanos; Omalizumab/efeitos adversos; Antiasmáticos/uso terapêutico; Imunoglobulina E; Resultado do Tratamento; Asma/diagnóstico; Asma/tratamento farmacológico; Biomarcadores

Palavras-chave

Omalizumab; allergic severe asthma; biomarker; meta-analysis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma / Antiasmáticos Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Adult / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google